Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 2/2016

Open Access 01-02-2016 | Review

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

Authors: C. Corinaldesi, L. Di Luigi, A. Lenzi, C. Crescioli

Published in: Journal of Endocrinological Investigation | Issue 2/2016

Login to get access

Abstract

PDE5 inhibitors (PDE5i) are widely known as treatment for erectile dysfunction (ED). This favorable action has emerged as a “side effect” from pioneering studies when PDE5i have been originally proposed as treatment for coronary artery disease (CAD). PDE5i showed marginal benefits for CAD treatment; although disappointing for that indication, they improved systemic and pulmonary vasodilation and ameliorated general endothelial function. Therefore, PDE5i have been approved and licensed also for pulmonary artery hypertension (PAH), besides ED. Nowadays, fine-tuned biomolecular mechanisms of PDE5i are well recognized to be beneficial onto myocardial contractility and geometry, to reduce tissue fibrosis, hypertrophy and apoptosis. PDE5i consistently exert benefits on heart failure, infarct, cardiomyopathy. The concept that PDE5i likely blunt Th1-driven inflammatory processes, which shift the homeostatic balance from health to disease, has emerged; PDE5i seem to decrease the release of active biomolecules from cells to tissues interested by inflammation. In this view, following clinical and basic research progresses, PDE5i can be undoubtedly “re-allocated” for cardiac indications and, hopefully, they could be approved as therapeutic tools to treat and prevent heart disease. This review aims to summarize PDE5i different clinical applications, from past to present and future, focusing on their potential power as treatment for cardiac diseases.
Literature
1.
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511PubMedCrossRef
2.
3.
Rao YJ, Xi L (2009) Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 30:1–24PubMedPubMedCentralCrossRef
4.
5.
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520PubMedCrossRef
6.
Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L (2004) Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategy. J Mol Cell Cardiol 36:165–173PubMedCrossRef
7.
Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discovery 1:674–682PubMedCrossRef
8.
Glossmann H, Petrischor G, Bartsch G (1999) Molecular mechanisms of the effects of sildenafil (VIAGRA). Exp Gerontol 34:305–318PubMedCrossRef
9.
Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725–748PubMed
10.
Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD (2009) Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 14:243–253PubMedPubMedCentralCrossRef
11.
Liu H, Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501–1510PubMedPubMedCentralCrossRef
12.
Gurney ME, D’Amato EC, Burgin AB (2014) Phosphodiesterase-4 (PDE4) molecular pharmacology and alzheimer’s disease. Neurotherapeutics 12:49–56PubMedCentralCrossRef
13.
Soderling SH, Bayuga SJ, Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci 95:8991–8996PubMedPubMedCentralCrossRef
14.
Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, Housley W, Clark RB, Epstein PM, Brocke S (2010) PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One 5:e12011PubMedPubMedCentralCrossRef
15.
Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983–993PubMedCrossRef
16.
Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ (2010) Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci 107:8457–8462PubMedPubMedCentralCrossRef
17.
Lin CS, Lin G, Xin ZC, Lue TF (2006) Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 12:3439–3457PubMedCrossRef
18.
D’Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA (2002) Type 5 phosphodiesterase expression in the human vagina. Urology 60:191–195PubMedCrossRef
19.
Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E, Piccione E, Lenzi A, Jannini EA (2006) Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem and Biophys Res Commun 341:837–846CrossRef
20.
Carosa E, Castri A, Forcella C, Sebastiani G, Di Sante S, Gravina GL, Ronchi P, Cesarini V, Dolci S, Di Stasi S, Lenzi A, Jannini EA (2014) Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells. J Sex Med 11:1675–1684PubMedCrossRef
21.
22.
Montorsi F, Corbin J, Phillips S (2004) Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med 1:322–336PubMedCrossRef
23.
Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32:198–209PubMedCrossRef
24.
Bender AT, Beavo JA (2004) Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem Int 45:853–857PubMedCrossRef
25.
Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670PubMedCrossRef
26.
Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506–516PubMedCrossRef
27.
28.
Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L, Galan A (2008) Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye (Lond) 22:144–149CrossRef
29.
Polak K, Wimpissinger B, Berisha F, Georgopoulos M, Schmetterer L (2003) Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects. Invest Ophthalmol Vis Sci 44:4872–4876PubMedCrossRef
30.
Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145:2253–22563PubMedCrossRef
31.
Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 32:419–429PubMedCrossRef
32.
Corbin JD, Francis SH (2003) Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl 24:S38–S41PubMedCrossRef
33.
Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453–459PubMed
34.
Francis SH, Morris GZ, Corbin JD (2008) Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20:333–342PubMedCrossRef
35.
Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144–152PubMedCrossRef
36.
Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164–2171PubMedCrossRef
37.
Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 56:124–130PubMed
38.
Katz EG, Tan RB, Rittenberg D, Hellstrom WJ (2014) Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag 27:701–711
39.
Carson CC (2007) Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 34:507–515PubMedCrossRef
40.
Gupta M, Kovar A, Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987–1003PubMedCrossRef
41.
Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodi- esterase type 5 inhibitors. Expert Opin Pharmacother 14:1333–1344PubMedCrossRef
42.
Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K (2013) Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Therapeutic Advances Urol 5:35–41CrossRef
43.
Hatzimouratidis K, Hatzichristou DG (2005) A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 65:1621–1650PubMedCrossRef
44.
Corona G, Razzoli E, Forti G, Maggi M (2008) The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 31:799–808PubMedCrossRef
45.
Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F (2011) Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 8:3418–3432PubMedCrossRef
46.
Jannini EA, DeRogatis LR, Chung E, Brock GB (2012) How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 9:26–33PubMedCrossRef
47.
Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F (2009) Tadalafil and vardenafil vs. sildenafil: a review of patient-preference studies. BJU Int 103:1212–1217PubMedCrossRef
48.
Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084–1095PubMedCrossRef
49.
Chrysant SG, Chrysant GS (2012) The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hyper 14:644–649CrossRef
50.
Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, Trask BA, Day WW (2012) Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc 87:843–852PubMedPubMedCentralCrossRef
51.
Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35:1743–1751PubMedCrossRef
52.
Hamet P, Coquil JF, Bousseau-Lafortune S, Franks DJ, Tremblay J (1984) Cyclic GMP binding and phosphodiesterase: implication for platelet function. Adv Cyclic Nucleotide Protein Phosphorylation Res 16:119–136PubMed
53.
Reffelman T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239–244CrossRef
54.
Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates b-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15:1718–1726PubMedCrossRef
55.
Shenoy P, Agarwal V (2010) Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun Rev 9:511–515PubMedCrossRef
56.
Kukreja RC, Salloum FD, Das A, Kola S, Ockaili RA, Xi L (2011) Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clini Cardiol 16:e30–e35
57.
Mostafa T (2008) Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. J Sex Med 5:2502–2518PubMedCrossRef
58.
Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, Wort SJ, Bédard E, Gibbs JS, Bauersachs J, Hobbs AJ, Wilkins MR, Gatzoulis MA, Wharton J (2008) Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117:3020–3030PubMedCrossRef
59.
Foresta C, De Toni L, Di Mambro A, Garolla A, Ferlin A, Zuccarello D (2008) The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J Sex Med 6:369–372PubMedCrossRef
60.
Kukreja RC (2007) Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Clin Pharmacol 150:538–540CrossRef
61.
Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944–12955PubMedCrossRef
62.
Crescioli C, Sturli N, Sottili M, Bonini P, Lenzi A, Di Luigi L (2013) Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J Endocrinol Invest 36:1020–1026PubMed
63.
Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59:9–15PubMedCrossRef
64.
Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4:8–17PubMedCrossRef
65.
Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A (2012) Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circ 125:2323–2333CrossRef
66.
67.
68.
Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guérin P, Sagan C, Pacaud P, Loirand G (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146:1010–1018PubMedPubMedCentralCrossRef
69.
Zenzmaier C, Kern J, Sampson N, Heitz M, Plas E, Untergasser G, Berger P (2012) Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology 153:5546–5555PubMedCrossRef
70.
Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391–1402PubMedCrossRef
71.
Bella AJ, Deyoung LX, Al-Numi M, Brock GB (2007) Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 52:990–1005PubMedCrossRef
72.
Fries R, Shariat K, von Wilmowsky H, Böhm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed
73.
Takeda N, Manabe I (2011) Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Int J Inflamm 2011:535241CrossRef
74.
Ross RS (2004) Molecular and mechanical synergy: cross-talk between integrins and growth factor receptors. Cardiovasc Res 63:381–390PubMedCrossRef
75.
Sottili M, Cosmi L, Borgogni E, Sarchielli E, Maggi L, Francalanci M, Vannelli GB, Ronconi E, Adorini L, Annunziato F, Romagnani P, Serio M, Crescioli C (2009) Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Exp Cell Res 315:264–273PubMedCrossRef
76.
Crescioli C, Squecco R, Cosmi L, Sottili M, Gelmini S, Borgogni E, Sarchielli E, Scolletta S, Francini F, Annunziato F, Vannelli GB, Serio M (2008) Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 314:1337–1350PubMedCrossRef
77.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healty men. N Engl J Med 336:973–979PubMedCrossRef
78.
Romagnani P, Crescioli C (2012) CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 413:1364–1373PubMedCrossRef
79.
Crescioli C (2013) The role of immunological biomarkers in cardiac rejection. Curr Opin Organ Transplant 18:595–600PubMedCrossRef
80.
Scolletta S, Colletti M, Di Luigi L, Crescioli C (2013) Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Med Inflamm 2013:876319CrossRef
81.
Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L (2009) Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 182:4056–4064PubMedCrossRef
82.
Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187:129–134PubMedPubMedCentralCrossRef
83.
Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD (2001) Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193:975–980PubMedPubMedCentralCrossRef
84.
Crescioli C, Buonamano A, Scolletta S, Sottili M, Francalanci M, Giomarelli P, Biagioli B, Lisi G, Pradella F, Serio M, Romagnani P, Maccherini M (2009) Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplant 87:249–255CrossRef
85.
Yue Y, Gui J, Ai W, Xu W, Xiong S (2011) Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses. PLoS One 6:e18186PubMedPubMedCentralCrossRef
86.
Scolletta S, Buonamano A, Sottili M, Giomarelli P, Biagioli B, Vannelli GB, Serio M, Romagnani P, Crescioli C (2012) CXCL10 release in cardiopulmonary bypass: an in vivo and in vitro study. Biomed and Agin Pathol 2:187–194CrossRef
87.
van den Borne P, Quax PHA, Hoefer IE, Pasterkamp G (2014) The multifaceted functions of CXCL10 in cardiovascular disease. BioMed Res Int 2014:893106PubMedPubMedCentral
88.
Salari P, Abdollahi M (2012) Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 21:261–264PubMedCrossRef
89.
Zhuang XD, Long M, Li F, Hu X, Liao XX, Du ZM (2014) PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 172:581–587PubMedCrossRef
90.
Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, Deswal A, Hernandez AF, Lee KL, Braunwald E, Network The Heart Failure Clinical Research (2012) Phosphdiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail 5:653–659PubMedPubMedCentralCrossRef
91.
92.
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005) Chronic inhibition of cyclic gmp phosphodiesterase 5a prevents and reverses cardiac hypertrophy. Nat Med 11:214–222PubMedCrossRef
93.
Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238–248PubMedCrossRef
94.
Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB (2012) Differential expression of pde5 in failing and nonfailing human myocardium. Circ Heart Fail 5:79–86PubMedPubMedCentralCrossRef
95.
Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408–416PubMedPubMedCentralCrossRef
96.
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y (2010) Oxidative stress regulates left ventricular pde5 expression in the failing heart. Circulation 121:1474–1483PubMedPubMedCentralCrossRef
97.
Metadata
Title
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
Authors
C. Corinaldesi
L. Di Luigi
A. Lenzi
C. Crescioli
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 2/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0340-5

Other articles of this Issue 2/2016

Journal of Endocrinological Investigation 2/2016 Go to the issue

Original Article

Thyroid Hürthle cell tumors: research of potential markers of malignancy

Original Article

Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis

Original Article

Neuronal distress induced by low extracellular sodium in vitro is partially reverted by the return to normal sodium

Endocrinology and Art

Antonello da Messina: Virgin Annunciate

Original Article

A non-invasive prevention program model for the assessment of osteoporosis in the early postmenopausal period: a pilot study on FRAX® and QUS tools advantages

Original Article

d-Aspartic acid stimulates steroidogenesis through the delay of LH receptor internalization in a mammalian Leydig cell line
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits